Previous 10 | Next 10 |
home / stock / giflf / giflf news
2023-07-05 10:56:31 ET Summary Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering...
2023-05-09 22:36:06 ET Grifols, S.A. (GRFS) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participa...
We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by managers who think and act as owne...
FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...
Grifols currently trading at a 30% discount to European specialty pharma. Biotest AG Investment analysis. Biotest R&D not priced in. For further details see: Grifols: Short-Term Turbulence But Long-Term Upside
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the longer-term growth outlook. With the valuation discount to CSL widening to unwa...
The following slide deck was published by Grifols, S.A. in conjunction with this event. For further details see: Grifols presents at 2021 investor and analyst day - slideshow
Grifols operates in the very attractive and lucrative plasma business. The plasma-supply chain has been disrupted by the pandemic but the situation should normalize with the vaccination. Even though some new medicines could potentially disrupt the market, we believe related fears ...
DRACO GLOBAL's value proposition is to invest in the best of two worlds: mega-caps known to all, and the other extreme, unknown micro-caps with nil or low analyst coverage. We look for a scalable business model, the existence of long-term secular growth, attractive sector structure, p...
News, Short Squeeze, Breakout and More Instantly...
Grifols SA Barcelona Company Name:
GIFLF Stock Symbol:
OTCMKTS Market:
Grifols SA Barcelona Website:
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
New York City, NY: April 09, 2020 – Recent Research and Future Market Potential of Automated Blood Processing Equipment Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the report is to offer updates and inform...